Journal of Infection and Public Health
High-dose sulbactam for extensively drug-resistant
By Jiaxin Yu, Zhiqiu He, Yunmeng Pang and 3 others.
Abstract
Objectives
The therapeutic effect and tolerability of sulbactam, at a daily dose of at least 9 g, were assessed in critically ill individuals who acquired extensively drug-resistant Acinetobacter baumannii (XDR-AB) infection.
Methods
This single-center retrospective cohort evaluated a primary composite endpoint of death from any cause or invasive mechanical ventilation (IMV) within 28 days. Secondary endpoints comprising the 14-day composite outcome, IMV-free and ICU-free days through day 28.